|Mr. Stanley Charles Erck||Chief Exec. Officer, Pres and Director||625.38k||1.56M||69|
|Mr. Barclay A. Phillips||Chief Financial Officer, Sr. VP and Treasurer||370.75k||N/A||54|
|Mr. John Joseph Trizzino B.S., M.B.A.||Sr. VP of Commercial Operations||366.89k||N/A||57|
|Mr. John A. Herrmann III, J.D.||Sr. VP, Gen. Counsel and Corp. Sec.||342.5k||N/A||51|
|Dr. Gregory M. Glenn M.D.||Pres of R&D||448.75k||N/A||63|
Novavax, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company develops respiratory syncytial virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III development stage; older adults in Phase II development stage; and children six months to five years of age in Phase I development stage. It also develops Ebola GP vaccine in Phase 1 clinical trial; preclinical programs for Zika virus; and seasonal influenza and a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Novavax, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 7. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 9; Compensation: 5.